SVB Leerink Equities Analysts Lower Earnings Estimates for Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc. (NASDAQ:FUSNGet Rating) – Research analysts at SVB Leerink cut their FY2024 EPS estimates for shares of Fusion Pharmaceuticals in a note issued to investors on Monday, May 22nd. SVB Leerink analyst F. Khurshid now forecasts that the company will post earnings of ($1.59) per share for the year, down from their previous forecast of ($1.45). The consensus estimate for Fusion Pharmaceuticals’ current full-year earnings is ($1.77) per share.

A number of other brokerages have also commented on FUSN. Morgan Stanley cut their price objective on shares of Fusion Pharmaceuticals from $19.00 to $10.00 and set an “overweight” rating on the stock in a report on Friday, January 27th. Brookline Capital Management reiterated a “buy” rating on shares of Fusion Pharmaceuticals in a report on Monday, February 13th. Finally, B. Riley restated a “buy” rating and issued a $10.00 target price on shares of Fusion Pharmaceuticals in a research note on Thursday, March 30th. Seven research analysts have rated the stock with a buy rating, According to data from, the company presently has a consensus rating of “Buy” and an average price target of $8.67.

Fusion Pharmaceuticals Stock Down 1.2 %

Shares of Fusion Pharmaceuticals stock opened at $4.25 on Wednesday. The company has a fifty day moving average price of $4.05 and a 200 day moving average price of $3.57. The company has a current ratio of 12.73, a quick ratio of 12.73 and a debt-to-equity ratio of 0.17. Fusion Pharmaceuticals has a twelve month low of $1.98 and a twelve month high of $5.22. The stock has a market cap of $271.35 million, a price-to-earnings ratio of -2.14 and a beta of -1.14.

Fusion Pharmaceuticals (NASDAQ:FUSNGet Rating) last announced its quarterly earnings results on Thursday, March 16th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.02. Fusion Pharmaceuticals had a negative net margin of 10,176.33% and a negative return on equity of 49.39%. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of FUSN. Perceptive Advisors LLC bought a new position in Fusion Pharmaceuticals in the 1st quarter worth about $10,405,000. Federated Hermes Inc. grew its position in Fusion Pharmaceuticals by 81.4% in the 1st quarter. Federated Hermes Inc. now owns 5,849,100 shares of the company’s stock worth $22,051,000 after purchasing an additional 2,625,000 shares during the last quarter. Braidwell LP bought a new position in shares of Fusion Pharmaceuticals in the fourth quarter valued at approximately $6,300,000. FMR LLC boosted its holdings in shares of Fusion Pharmaceuticals by 73.9% in the first quarter. FMR LLC now owns 4,681,457 shares of the company’s stock valued at $17,649,000 after acquiring an additional 1,989,403 shares in the last quarter. Finally, Sphera Funds Management LTD. bought a new position in shares of Fusion Pharmaceuticals in the first quarter valued at approximately $4,839,000. Institutional investors own 59.39% of the company’s stock.

About Fusion Pharmaceuticals

(Get Rating)

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.

Featured Articles

Earnings History and Estimates for Fusion Pharmaceuticals (NASDAQ:FUSN)

Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with's FREE daily email newsletter.